{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:39:59Z","timestamp":1753889999257,"version":"3.41.2"},"reference-count":81,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Heart Failure (HF) is characterized by an elevated readmission rate, with almost 50% of events occurring after the first episode over the first 6 months of the post-discharge period. In this context, the vulnerable phase represents the period when patients elapse from a sub-acute to a more stabilized chronic phase. The lack of an accurate approach for each HF subtype is probably the main cause of the inconclusive data in reducing the trend of recurrent hospitalizations. Most care programs are based on the main diagnosis and the HF stages, but a model focused on the specific HF etiology is lacking. The HF clinic route based on the HF etiology and the underlying diseases responsible for HF could become an interesting approach, compared with the traditional programs, mainly based on non-specific HF subtypes and New York Heart Association class, rather than on detailed etiologic and epidemiological data. This type of care may reduce the 30-day readmission rates for HF, increase the use of evidence-based therapies, prevent the exacerbation of each comorbidity, improve patient compliance, and decrease the use of resources. For all these reasons, we propose a dedicated outpatient HF program with a daily practice scenario that could improve the early identification of symptom progression and the quality-of-life evaluation, facilitate the access to diagnostic and laboratory tools and improve the utilization of financial resources, together with optimal medical titration and management.<\/jats:p>","DOI":"10.31083\/j.rcm2203077","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T02:35:45Z","timestamp":1632623745000},"source":"Crossref","is-referenced-by-count":2,"title":["The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease"],"prefix":"10.31083","volume":"22","author":[{"given":"Matteo","family":"Beltrami","sequence":"first","affiliation":[{"name":"Cardiology Unit, San Giovanni di Dio Hospital, 50142 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bartolini","sequence":"first","affiliation":[{"name":"Cardiology Unit, San Giovanni di Dio Hospital, 50142 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Milli","sequence":"first","affiliation":[{"name":"Cardiology Unit, San Giovanni di Dio Hospital, 50142 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"first","affiliation":[{"name":"Cardiovascular Diseases Unit, Department of Internal Medicine, Le Scotte Hospital, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Khazanie P, Liang L, Qualls LG, Curtis LH, Fonarow GC, Hammill BG, et al. Outcomes of Medicare Beneficiaries with Heart Failure and Atrial Fibrillation. JACC: Heart Failure. 2014; 2: 41\u201348.","DOI":"10.1016\/j.jchf.2013.11.002"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal. 2005; 149: 209\u2013216.","DOI":"10.1016\/j.ahj.2004.08.005"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"O\u2019Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal. 2008; 156: 662\u2013673.","DOI":"10.1016\/j.ahj.2008.04.030"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, et al. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circulation. Heart Failure. 2012; 5: 414\u2013421.","DOI":"10.1161\/CIRCHEARTFAILURE.111.964791"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"O\u2019Connor CM, Miller AB, Blair JEA, Konstam MA, Wedge P, Bahit MC, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. American Heart Journal. 2010; 159: 841\u2013849.","DOI":"10.1016\/j.ahj.2010.02.023"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ross JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, et al. Statistical models and patient predictors of readmission for heart failure: a systematic review. Archives of Internal Medicine. 2008; 168: 1371\u20131386.","DOI":"10.1001\/archinte.168.13.1371"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. European Journal of Heart Failure. 2016; 18: 402\u2013410.","DOI":"10.1002\/ejhf.471"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Stauffer BD, Fullerton C, Fleming N, Ogola G, Herrin J, Stafford PM, et al. Effectiveness and cost of a transitional care program for heart failure: a prospective study with concurrent controls. Archives of Internal Medicine. 2011; 171: 1238\u20131243.","DOI":"10.1001\/archinternmed.2011.274"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Holland R, Battersby J, Harvey I, Lenaghan E, Smith J, Hay L. Systematic review of multidisciplinary interventions in heart failure. Hear. 2005; 91: 899\u2013906.","DOI":"10.1136\/hrt.2004.048389"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Buck HG, Stromberg A, Chung ML, Donovan KA, Harkness K, Howard AM, et al. A systematic review of heart failure dyadic self-care interventions focusing on intervention components, contexts, and outcomes. International Journal of Nursing Studies. 2018; 77: 232\u2013242.","DOI":"10.1016\/j.ijnurstu.2017.10.007"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Palazzuoli A, Evangelista I, Ruocco G, Lombardi C, Giovannini V, Nuti R, et al. Early readmission for heart failure: an avoidable or ineluctable debacle? International Journal of Cardiology. 2019; 277: 186\u2013195.","DOI":"10.1016\/j.ijcard.2018.09.039"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gustafsson F, Arnold JMO. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. European Heart Journal. 2004; 25: 1596\u20131604.","DOI":"10.1016\/j.ehj.2004.06.023"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, B\u00f6hm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 2016; 37: 1850\u20131858.","DOI":"10.1093\/eurheartj\/ehv727"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: a Review and Meta-Analysis. JACC: Cardiovascular Imaging. 2018; 11: 1274\u20131284.","DOI":"10.1016\/j.jcmg.2018.03.006"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Halliday BP, Baksi AJ, Gulati A, Ali A, Newsome S, Izgi C, et al. Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement. JACC: Cardiovascular Imaging. 2019; 12: 1645\u20131655.","DOI":"10.1016\/j.jcmg.2018.07.015"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. Journal of Heart and Lung Transplantation. 2016; 35: 1\u201323.","DOI":"10.1016\/j.healun.2015.10.023"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sinagra G, Iorio A, Merlo M, Cannat\u00e0 A, Stolfo D, Zambon E, et al. Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy. International Journal of Cardiology. 2016; 223: 596\u2013603.","DOI":"10.1016\/j.ijcard.2016.07.232"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Marrow BA, Cook SA, Prasad SK, McCann GP. Emerging Techniques for Risk Stratification in Nonischemic Dilated Cardiomyopathy: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2020; 75: 1196\u20131207.","DOI":"10.1016\/j.jacc.2019.12.058"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Hirashiki A, Kondo T, Okumura T, Kamimura Y, Nakano Y, Fukaya K, et al. Cardiopulmonary Exercise Testing as a Tool for Diagnosing Pulmonary Hypertension in Patients with Dilated Cardiomyopathy. Annals of Noninvasive Electrocardiology. 2016; 21: 263\u2013271.","DOI":"10.1111\/anec.12308"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. Journal of the American College of Cardiology. 2011; 57: 1468\u20131476.","DOI":"10.1016\/j.jacc.2010.11.030"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. Journal of the American College of Cardiology. 2011; 58: 1112\u20131118.","DOI":"10.1016\/j.jacc.2011.05.033"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Finocchiaro G, Merlo M, Sheikh N, De Angelis G, Papadakis M, Olivotto I, et al. The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. European Journal of Heart Failure. 2020; 22: 1097\u20131107.","DOI":"10.1002\/ejhf.1815"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Gualeni A, D\u2019Aloia A, Gentilini A, Pagani M, Giordano A, Faggiano P. Effects of maximally tolerated oral therapy on the six-minute walking test in patients with chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology. 1998; 81: 1370\u20131372.","DOI":"10.1016\/S0002-9149(98)00172-6"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017; 136: 2420\u20132436.","DOI":"10.1161\/CIRCULATIONAHA.117.029267"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ciabatti M, Fumagalli C, Beltrami M, Vignini E, Martinese L, Tomberli A, et al. Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. International Journal of Cardiology. 2020; 318: 94\u2013100.","DOI":"10.1016\/j.ijcard.2020.07.036"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 396: 759\u2013769.","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Elliott P, Anastasakis A, Borger M, Borggrefe MF, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. European Heart Journal. 2014; 35: 2733\u20132779.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Re F, Zachara E, Avella A, Baratta P, di Mauro M, Uguccioni M, et al. Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: a combined cardiopulmonary-echocardiographic study. International Journal of Cardiology. 2017; 227: 743\u2013750.","DOI":"10.1016\/j.ijcard.2016.10.067"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Lazzeroni E, Picano E, Dodi C, Morozzi L, Chiriatti GP, Lu C, et al. Dipyridamole echocardiography for diagnosis of coexistent coronary artery disease in hypertrophic cardiomyopathy. American Journal of Cardiology. 1995; 75: 810\u2013813.","DOI":"10.1016\/S0002-9149(99)80417-2"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Cortigiani L, Rigo F, Gherardi, Galderisi M, Sicari R, Picano E. Prognostic implications of coronary flow reserve in left anterior descending coronary artery in hypertrophic cardiomyopathy. American Journal of Cardiology. 2008; 102: 926\u2013932.","DOI":"10.1016\/j.amjcard.2008.08.023"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Quarta G, Aquaro GD, Pedrotti P, Pontone G, Dellegrottaglie S, Iacovoni A, et al. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. European Heart Journal: Cardiovascular Imaging. 2018; 19: 601\u2013610.","DOI":"10.1093\/ehjci\/jex323"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Pattern of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circulation: Heart Failure. 2012; 5: 535\u2013546.","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Salerno M, Sharif B, Arheden H, Kumar A, Axel L, Li D, et al. Recent Advances in Cardiovascular Magnetic Resonance. Circulation: Cardiovascular Imaging. 2017; 10: e003951.","DOI":"10.1161\/CIRCIMAGING.116.003951"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Levine J, Collins JD, Ogele E, Murtagh G, Carr JC, Bonow RO, et al. Relation of Late Gadolinium Enhancement and Extracellular Volume Fraction to Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. American Journal of Cardiology. 2020; 131: 104\u2013108.","DOI":"10.1016\/j.amjcard.2020.06.040"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Raiker N, Vullaganti S, Collins JD, Allen BD, Choudhury L. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy. International Journal of Cardiovascular Imaging. 2020; 36: 1147\u20131156.","DOI":"10.1007\/s10554-020-01808-6"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Coats CJ, Rantell K, Bartnik A, Patel A, Mist B, McKenna WJ, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circulation. Heart Failure. 2015; 8: 1022\u20131031.","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018; 138: 1387\u20131398.","DOI":"10.1161\/CIRCULATIONAHA.117.033200"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal. 2015; 36: 2585\u20132594.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine. 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis. JACC: Cardiovascular Imaging. 2020; 13: 1299\u20131310.","DOI":"10.1016\/j.jcmg.2020.03.010"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Journal of Heart Failure. 2021; 42: 1554\u20131568","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Briceno N, Schuster A, Lumley M, Perera D. Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation. Heart. 2016; 102: 397\u2013406.","DOI":"10.1136\/heartjnl-2015-308037"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Felker GM, Shaw LK, O\u2019Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. Journal of the American College of Cardiology. 2002; 39: 210\u2013218.","DOI":"10.1016\/S0735-1097(01)01738-7"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Sutton MGSJ, Sharpe N. Left Ventricular Remodeling after Myocardial Infarction. Circulation. 2000; 101: 2981\u20132988.","DOI":"10.1161\/01.CIR.101.25.2981"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2020; 42: 1289\u20131367.","DOI":"10.1093\/eurheartj\/ehaa909"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Perry AS, Mann DL, Brown DL. Improvement of ejection fraction and mortality in ischaemic heart failure. Heart. 2021; 107: 326\u2013331.","DOI":"10.1136\/heartjnl-2020-316975"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"de Waha S, Patel MR, Granger CB, Ohman EM, Maehara A, Eitel I, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. European Heart Journal. 2017; 38: 3502\u20133510.","DOI":"10.1093\/eurheartj\/ehx414"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Palazzuoli A, Beltrami M, Gennari L, Dastidar AG, Nuti R, McAlindon E, et al. The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. International Journal of Cardiovascular Imaging. 2015; 31: 1037\u20131044.","DOI":"10.1007\/s10554-015-0657-3"},{"key":"ref49","unstructured":"Hombach V, Merkle N, Bernhard P, Rasche V, Rottbauer W. Prognostic significance of cardiac magnetic resonance imaging: Update 2010. Cardiology Journal. 2010; 17: 549\u2013557."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. Journal of the American College of Cardiology. 2005; 45: 1104\u20131108.","DOI":"10.1016\/j.jacc.2004.12.057"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Roes SD, Kelle S, Kaandorp TAM, Kokocinski T, Poldermans D, Lamb HJ, et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. American Journal of Cardiology. 2007; 100: 930\u2013936.","DOI":"10.1016\/j.amjcard.2007.04.029"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Kinnel M, Sanguineti F, Pezel T, Unterseeh T, Hovasse T, Toupin S, et al. Prognostic value of vasodilator stress perfusion CMR in patients with previous coronary artery bypass graft. European Heart Journal-Cardiovascular Imaging. 2020; 13: jeaa316.","DOI":"10.1016\/j.acvdsp.2020.10.056"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Frank S, Johnson A, Ross J. Natural history of valvular aortic stenosis. British Heart Journal. 1973; 35: 41\u201346.","DOI":"10.1136\/hrt.35.1.41"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. New England Journal of Medicine. 2010; 363: 1597\u20131607.","DOI":"10.1056\/NEJMoa1008232"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, S\u00f8ndergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate- risk patients. New England Journal of Medicine. 2017; 376: 1321\u20131331.","DOI":"10.1056\/NEJMoa1700456"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Thyregod HGH, Steinbr\u00fcchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Valve Stenosis: 1-Year Results from the all-Comers NOTION Randomized Clinical Trial. Journal of the American College of Cardiology. 2015; 65: 2184\u20132194.","DOI":"10.1016\/j.jacc.2015.03.014"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143: e72\u2013e227.","DOI":"10.1161\/CIR.0000000000000923"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Elbaz-Greener G, Ghanim D, Kusniec F, Rabin A, Sudarsky D, Carasso S, et al. Pre- and Post-Transcatheter Aortic Valve Replacement Serum Brain Natriuretic Peptide Levels and all-Cause Mortality. Cardiology. 2020; 145: 813\u2013821.","DOI":"10.1159\/000509857"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Clavel M, Magne J, Pibarot P. Low-gradient aortic stenosis. European Heart Journal. 2016; 37: 2645\u20132657.","DOI":"10.1093\/eurheartj\/ehw096"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Anjan VY, Herrmann HC, Pibarot P, Stewart WJ, Kapadia S, Tuzcu EM, et al. Evaluation of flow after transcatheter aortic valve replacement in patients with low-flow aortic stenosis: a secondary analysis of the PARTNER randomized clinical trial. JAMA Cardiology. 2016; 1: 584.","DOI":"10.1001\/jamacardio.2016.0759"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2017; 38: 2739\u20132791.","DOI":"10.1016\/j.rec.2017.12.013"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Namazi F, Vo NM, Delgado V. Imaging of the mitral valve: role of echocardiography, cardiac magnetic resonance, and cardiac computed tomography. Current Opinion in Cardiology. 2020; 35: 435\u2013444.","DOI":"10.1097\/HCO.0000000000000779"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Obadia J, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. New England Journal of Medicine. 2018; 379: 2297\u20132306.","DOI":"10.1056\/NEJMoa1805374"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. New England Journal of Medicine. 2018; 379: 2307\u20132318.","DOI":"10.1056\/NEJMoa1806640"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Katz WE, Conrad Smith AJ, Crock FW, Cavalcante JL. Echocardiographic evaluation and guidance for MitraClip procedure. Cardiovascular Diagnosis and Therapy. 2017; 7: 616\u2013632.","DOI":"10.21037\/cdt.2017.07.04"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Colivicchi F, Di Fusco S, Magnanti M, Cipriani M, Imperoli G. The impact of the COVID-19 pandemic and Italian lockdown measures on clinical presentation and management of acute heart failure. Journal of Cardiac Failure. 2020; 26: 464\u2013465.","DOI":"10.1016\/j.cardfail.2020.05.007"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, et al. Effectiveness of Remote Patient Monitoring after Discharge of Hospitalized Patients with Heart Failure: the Better Effectiveness after Transition \u2013 Heart Failure (BEAT-HF) Randomized Clinical Trial. JAMA Internal Medicine. 2016; 176: 310\u2013318.","DOI":"10.1001\/jamainternmed.2015.7712"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Rahimi K, Nazarzadeh M, Pinho GA. Home monitoring with technology-supported management in chronic heart failure: a randomized trial. Heart. 2020; 106: 1573\u20131578.","DOI":"10.1136\/heartjnl-2020-316773"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Mohebali D, Kittleson MM. Remote monitoring in heart failure: current and emerging technologies in the context of the pandemic. Heart. 2021; 107: 366\u2013372.","DOI":"10.1136\/heartjnl-2020-318062"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011; 377: 658\u2013666.","DOI":"10.1016\/S0140-6736(11)60101-3"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Lala A, Barghash MH, Giustino G, Alvarez\u2010Garcia J, Konje S, Parikh A, et al. Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. ESC Heart Failure. 2021; 8: 1047\u20131054.","DOI":"10.1002\/ehf2.13026"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A, et al. A Multisensor Algorithm Predicts Heart Failure Events in Patients with Implanted Devices: Results from the MultiSENSE Study. JACC: Heart Failure. 2017; 5: 216\u2013225.","DOI":"10.1016\/j.jchf.2016.12.011"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Almufleh A, Ahluwalia M, Givertz MM, Weintraub J, Young M, Cooper I, et al. Short-term Outcomes in Ambulatory Heart Failure during the COVID-19 Pandemic: Insights from Pulmonary Artery Pressure Monitoring. Journal of Cardiac Failure. 2020; 26: 633\u2013634.","DOI":"10.1016\/j.cardfail.2020.05.021"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Bayoumy K, Gaber M, Elshafeey A, Mhaimeed O, Dineen EH, Marvel FA, et al. Smart wearable devices in cardiovascular care: where we are and how to move forward. Nature Reviews Cardiology. 2021; 18: 581\u2013599.","DOI":"10.1038\/s41569-021-00522-7"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Oseran AS, Afari ME, Barrett CD, Lewis GD, Thomas SS. Beyond the stethoscope: managing ambulatory heart failure during the COVID\u201019 pandemic. ESC Heart Failure. 2021; 8: 999\u20131006.","DOI":"10.1002\/ehf2.13201"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Maurizi N, Faragli A, Imberti J, Briante N, Targetti M, Baldini K, et al. Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart\u00ae). International Journal of Cardiology. 2017; 236: 249\u2013252.","DOI":"10.1016\/j.ijcard.2017.02.027"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Satici S, Iyngkaran P, Andrew S, Patil A, Bidargaddi N, Battersby M, et al. Rethinking heart failure care and health technologies from early COVID-19 experiences - a narrative review. Reviews in Cardiovascular Medicine. 2021; 22: 105.","DOI":"10.31083\/j.rcm.2021.01.272"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan B, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018; 392: 1047\u20131057.","DOI":"10.1016\/S0140-6736(18)31880-4"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Verhestraeten C, Weijers G, Debleu D, Ciarka A, Goethals M, Droogmans S, et al. Diagnosis, treatment, and follow-up of heart failure patients by general practitioners: A Delphi consensus statement. PLoS ONE. 2020; 15: e0244485.","DOI":"10.1371\/journal.pone.0244485"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Afonso Nogueira M, Ferreira F, Raposo AF, M\u00f3nica L, Sim\u00f5es Dias S, Vasconcellos R, et al. Impact of telemedicine on the management of heart failure patients during coronavirus disease 2019 pandemic. ESC Heart Failure. 2021; 8: 1150\u20131155.","DOI":"10.1002\/ehf2.13157"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Bonow RO, Bennett S, Casey DE Jr, Ganiats TG, Hlatky MA, Konstam MA, et al. ACC\/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation. 2005; 112: 1853\u20131887.","DOI":"10.1161\/CIRCULATIONAHA.105.170072"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/3\/10.31083\/j.rcm2203077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:17:48Z","timestamp":1732727868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/3\/10.31083\/j.rcm2203077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["1632453065083-1418249639"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2203077","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"article-number":"677"}}